These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29157102)

  • 1. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.
    Li JA; Song C; Rong Y; Kuang T; Wang D; Xu X; Yuan J; Luo K; Qin B; Nowsheen S; Lou Z; Lou W
    Cell Cycle; 2018; 17(2):191-199. PubMed ID: 29157102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
    Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
    Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
    Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis.
    Wu MH; Lee CY; Huang TJ; Huang KY; Tang CH; Liu SH; Kuo KL; Kuan FC; Lin WC; Shi CS
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death.
    Hu L; Bai ZG; Ma XM; Bai N; Zhang ZT
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8273-8280. PubMed ID: 30556867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
    Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
    Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
    Lan H; Tang Z; Jin H; Sun Y
    Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.
    Zheng W; Luo Z; Zhang J; Min P; Li W; Xu D; Zhang Z; Xiong P; Liang H; Liu J
    Mol Med Rep; 2017 May; 15(5):2795-2801. PubMed ID: 28447739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma.
    Zhang Y; Shi CC; Zhang HP; Li GQ; Li SS
    Oncotarget; 2016 Jul; 7(29):45263-45274. PubMed ID: 27223074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
    Urrutia G; Salmonson A; Toro-Zapata J; de Assuncao TM; Mathison A; Dusetti N; Iovanna J; Urrutia R; Lomberk G
    Mol Cancer Res; 2020 Mar; 18(3):448-462. PubMed ID: 31822519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
    Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
    Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
    Jazaeri AA; Shibata E; Park J; Bryant JL; Conaway MR; Modesitt SC; Smith PG; Milhollen MA; Berger AJ; Dutta A
    Mol Cancer Ther; 2013 Oct; 12(10):1958-67. PubMed ID: 23939375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
    Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
    Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLN4924 therapy as a novel approach in cancer treatment modalities.
    Oladghaffari M; Islamian JP; Baradaran B; Monfared AS
    J Chemother; 2016 Apr; 28(2):74-82. PubMed ID: 26292710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
    Bahjat M; de Wilde G; van Dam T; Maas C; Bloedjes T; Bende RJ; van Noesel CJM; Luijks DM; Eldering E; Kersten MJ; Guikema JEJ
    Cell Cycle; 2019 Sep; 18(18):2307-2322. PubMed ID: 31349760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
    Cooper J; Xu Q; Zhou L; Pavlovic M; Ojeda V; Moulick K; de Stanchina E; Poirier JT; Zauderer M; Rudin CM; Karajannis MA; Hanemann CO; Giancotti FG
    Mol Cancer Ther; 2017 Aug; 16(8):1693-1704. PubMed ID: 28468780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.